Analysis of glycemic status in diabetes-naïve patients on statins: A hospital-based cross-sectional study

Sereen Rose Thomson, Bharti Chogtu, Ranjan Shetty, Tom Devasia

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Randomized controlled trials, observational studies, and meta-analysis suggest risk of hyperglycemia in patients on statins, and this association is being viewed with renewed interest globally. The present study has tried to explore the possible diabetogenic effect of statins, the mechanism of this effect, and various comorbidities associated with this causation. MATERIALS AND METHODS: This cross-sectional study was carried out at the Department of Cardiology from October 2015 to March 2017. Patients on statins for at least 1 year and normoglycemic at the time of statin initiation were recruited in the study. The outcome of the present study was development of new-onset diabetes mellitus (NODM). Blood glucose levels and insulin levels were estimated. Other adverse reactions of statins and associated comorbidities in the patients were recorded. Descriptive statistics were used to analyze adverse drug reactions. RESULTS: A total of 104 patients met the inclusion criteria, of which eight patients (7.7%) developed NODM and 4 (3.8%) developed prediabetes. Atorvastatin 40 mg was most commonly prescribed statin. About 25% of patients taking atorvastatin 80 mg developed diabetes CONCLUSION: Statins have a mild-to-moderate risk of developing NODM. The dose of statins is an important factor that increases the risk of diabetes in statin users.

Original languageEnglish
Pages (from-to)320-325
Number of pages6
JournalIndian Journal of Pharmacology
Volume50
Issue number6
DOIs
Publication statusPublished - 01-11-2018

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cross-Sectional Studies
Diabetes Mellitus
Comorbidity
Prediabetic State
Cardiology
Drug-Related Side Effects and Adverse Reactions
Hyperglycemia
Causality
Observational Studies
Blood Glucose
Meta-Analysis
Randomized Controlled Trials
Outcome Assessment (Health Care)
Insulin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{d201fffb0d534d0fb6fc512535377b8a,
title = "Analysis of glycemic status in diabetes-na{\"i}ve patients on statins: A hospital-based cross-sectional study",
abstract = "INTRODUCTION: Randomized controlled trials, observational studies, and meta-analysis suggest risk of hyperglycemia in patients on statins, and this association is being viewed with renewed interest globally. The present study has tried to explore the possible diabetogenic effect of statins, the mechanism of this effect, and various comorbidities associated with this causation. MATERIALS AND METHODS: This cross-sectional study was carried out at the Department of Cardiology from October 2015 to March 2017. Patients on statins for at least 1 year and normoglycemic at the time of statin initiation were recruited in the study. The outcome of the present study was development of new-onset diabetes mellitus (NODM). Blood glucose levels and insulin levels were estimated. Other adverse reactions of statins and associated comorbidities in the patients were recorded. Descriptive statistics were used to analyze adverse drug reactions. RESULTS: A total of 104 patients met the inclusion criteria, of which eight patients (7.7{\%}) developed NODM and 4 (3.8{\%}) developed prediabetes. Atorvastatin 40 mg was most commonly prescribed statin. About 25{\%} of patients taking atorvastatin 80 mg developed diabetes CONCLUSION: Statins have a mild-to-moderate risk of developing NODM. The dose of statins is an important factor that increases the risk of diabetes in statin users.",
author = "Thomson, {Sereen Rose} and Bharti Chogtu and Ranjan Shetty and Tom Devasia",
year = "2018",
month = "11",
day = "1",
doi = "10.4103/ijp.IJP_132_18",
language = "English",
volume = "50",
pages = "320--325",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "6",

}

Analysis of glycemic status in diabetes-naïve patients on statins : A hospital-based cross-sectional study. / Thomson, Sereen Rose; Chogtu, Bharti; Shetty, Ranjan; Devasia, Tom.

In: Indian Journal of Pharmacology, Vol. 50, No. 6, 01.11.2018, p. 320-325.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of glycemic status in diabetes-naïve patients on statins

T2 - A hospital-based cross-sectional study

AU - Thomson, Sereen Rose

AU - Chogtu, Bharti

AU - Shetty, Ranjan

AU - Devasia, Tom

PY - 2018/11/1

Y1 - 2018/11/1

N2 - INTRODUCTION: Randomized controlled trials, observational studies, and meta-analysis suggest risk of hyperglycemia in patients on statins, and this association is being viewed with renewed interest globally. The present study has tried to explore the possible diabetogenic effect of statins, the mechanism of this effect, and various comorbidities associated with this causation. MATERIALS AND METHODS: This cross-sectional study was carried out at the Department of Cardiology from October 2015 to March 2017. Patients on statins for at least 1 year and normoglycemic at the time of statin initiation were recruited in the study. The outcome of the present study was development of new-onset diabetes mellitus (NODM). Blood glucose levels and insulin levels were estimated. Other adverse reactions of statins and associated comorbidities in the patients were recorded. Descriptive statistics were used to analyze adverse drug reactions. RESULTS: A total of 104 patients met the inclusion criteria, of which eight patients (7.7%) developed NODM and 4 (3.8%) developed prediabetes. Atorvastatin 40 mg was most commonly prescribed statin. About 25% of patients taking atorvastatin 80 mg developed diabetes CONCLUSION: Statins have a mild-to-moderate risk of developing NODM. The dose of statins is an important factor that increases the risk of diabetes in statin users.

AB - INTRODUCTION: Randomized controlled trials, observational studies, and meta-analysis suggest risk of hyperglycemia in patients on statins, and this association is being viewed with renewed interest globally. The present study has tried to explore the possible diabetogenic effect of statins, the mechanism of this effect, and various comorbidities associated with this causation. MATERIALS AND METHODS: This cross-sectional study was carried out at the Department of Cardiology from October 2015 to March 2017. Patients on statins for at least 1 year and normoglycemic at the time of statin initiation were recruited in the study. The outcome of the present study was development of new-onset diabetes mellitus (NODM). Blood glucose levels and insulin levels were estimated. Other adverse reactions of statins and associated comorbidities in the patients were recorded. Descriptive statistics were used to analyze adverse drug reactions. RESULTS: A total of 104 patients met the inclusion criteria, of which eight patients (7.7%) developed NODM and 4 (3.8%) developed prediabetes. Atorvastatin 40 mg was most commonly prescribed statin. About 25% of patients taking atorvastatin 80 mg developed diabetes CONCLUSION: Statins have a mild-to-moderate risk of developing NODM. The dose of statins is an important factor that increases the risk of diabetes in statin users.

UR - http://www.scopus.com/inward/record.url?scp=85060658006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060658006&partnerID=8YFLogxK

U2 - 10.4103/ijp.IJP_132_18

DO - 10.4103/ijp.IJP_132_18

M3 - Article

AN - SCOPUS:85060658006

VL - 50

SP - 320

EP - 325

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 6

ER -